Trademark: 88877284
Word
VYROLOGIX
Status Date
Monday, September 5, 2022
Filing Date
Friday, April 17, 2020
Published for Opposition
Tuesday, December 8, 2020
Abandoned Date
Monday, September 5, 2022
5 therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor, for preventing and/or treating HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, respiratory diseases and disorders; therapeutic preparations for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, respiratory diseases and disorders; therapeutic preparations for the treatment of COVID-19
The mark consists of "VYROLOGIX" in stylized letters.
Color is not claimed as a feature of the mark.
Sep 6, 2022
Abandonment Notice E-Mailed - No Use Statement Filed
Sep 5, 2022
Abandonment - No Use Statement Filed
Feb 1, 2022
Notice Of Approval Of Extension Request E-Mailed
Jan 28, 2022
Sou Extension 2 Granted
Jan 28, 2022
Sou Extension 2 Filed
Jan 28, 2022
Teas Extension Received
Jul 15, 2021
Notice Of Approval Of Extension Request E-Mailed
Jul 13, 2021
Sou Extension 1 Granted
Jul 13, 2021
Sou Extension 1 Filed
Jul 13, 2021
Teas Extension Received
Feb 2, 2021
Noa E-Mailed - Sou Required From Applicant
Dec 8, 2020
Official Gazette Publication Confirmation E-Mailed
Dec 8, 2020
Published For Opposition
Nov 18, 2020
Notification Of Notice Of Publication E-Mailed
Nov 3, 2020
Approved For Pub - Principal Register
Oct 28, 2020
Assigned To Examiner
Apr 27, 2020
New Application Office Supplied Data Entered In Tram
Apr 21, 2020
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
